Skip to main content
. 2022 Dec 21;15(1):38. doi: 10.3390/cancers15010038

Figure 3.

Figure 3

Schematic representation of the mechanism underlying the action of margetuximab. Margetuximab is an Fc-optimized mAb that binds to ECD IV of the HER2 receptor, thus preventing the formation of HER2–HER2 homodimers and ligand-independent HER2–HER3, HER2–HER1, and HER2–HER4 complexes/heterodimers. It enhances ADCC, leads to tumor lysis, and inhibits the TK signaling cascade, thus limiting cancer cell proliferation, migration, invasion, and survival. Figures were generated using Microsoft PowerPoint and free templates obtained from https://smart.servier.com/ (accessed on 9 June 2022).